Last updated: August 7, 2026
Perphenazine and amitriptyline hydrochloride is a mature fixed-dose combination marketed historically under the Triavil brand and now supplied primarily as a generic prescription tablet. Its commercial profile is defined by low pricing, limited manufacturer investment, declining clinical use and the absence of meaningful remaining regulatory exclusivity. No public evidence indicates material standalone revenue, active branded commercialization or a significant modern patent barrier in the United States.
What is perphenazine and amitriptyline hydrochloride used for?
Perphenazine and amitriptyline hydrochloride combines a phenothiazine antipsychotic with a tricyclic antidepressant. The labeled indication is depressive illness accompanied by moderate-to-severe anxiety, agitation and tension.[1]
The product is available in tablet strengths that combine:
| Perphenazine |
Amitriptyline hydrochloride |
| 2 mg |
10 mg |
| 2 mg |
25 mg |
| 4 mg |
10 mg |
| 4 mg |
25 mg |
Perphenazine provides antipsychotic activity through dopamine receptor antagonism. Amitriptyline affects norepinephrine and serotonin reuptake and has anticholinergic, sedative and analgesic properties. The combination was developed for patients whose depressive symptoms included substantial agitation or anxiety.
Clinical use has narrowed because physicians can separately titrate antidepressants and antipsychotics, while newer medicines have better tolerability, safety monitoring and treatment-positioning profiles. The fixed combination also limits dose flexibility.
What are the principal safety constraints?
The product carries risks associated with both components. Perphenazine is subject to antipsychotic-class warnings, including tardive dyskinesia and increased mortality in elderly patients with dementia-related psychosis. Amitriptyline carries tricyclic-antidepressant risks, including cardiac conduction effects, overdose lethality and suicidality warnings applicable to antidepressant therapy.[1]
These risks reduce the product’s attractiveness relative to newer antidepressants and antipsychotics, particularly for long-term treatment and elderly patients.
When did Triavil lose exclusivity?
Triavil lost meaningful market exclusivity decades ago. The active ingredients are old small molecules, and the fixed-dose combination has been available in generic form for many years.
| Exclusivity category |
Current commercial position |
| New chemical entity exclusivity |
Expired |
| Original formulation exclusivity |
Expired |
| Fixed-dose combination exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No meaningful current protection |
| Biosimilar exclusivity |
Not applicable |
| Patent-based exclusivity |
No material remaining term indicated for the legacy product |
The product’s regulatory history predates the modern generic-drug framework. Any original patents covering perphenazine, amitriptyline or the historical combination would have expired long ago. The economic issue is therefore generic supply and demand, not loss of a near-term patent cliff.
What is the Orange Book status of perphenazine and amitriptyline hydrochloride?
The product is a conventional small-molecule tablet rather than a biologic or complex drug-delivery system. FDA Orange Book protection is not the principal commercial constraint.
The relevant Orange Book questions are whether an approved reference product has current listed patents or exclusivity and whether generic applicants must address those protections. For this legacy combination, no active Orange Book patent position is publicly associated with a commercially significant remaining exclusivity period. The product should be treated as an off-patent, multi-source prescription medicine.[2]
The Orange Book does not create a continuing exclusivity right merely because a product remains FDA-approved. It records patents and regulatory exclusivity connected to approved products. Once those rights expire, ANDA applicants can compete through the standard abbreviated pathway.
Are there active Paragraph IV challenges?
A commercially important Paragraph IV campaign is unlikely for this product. Paragraph IV litigation typically arises when a branded product has substantial revenue protected by listed patents. Perphenazine and amitriptyline hydrochloride has neither a modern branded revenue base nor an apparent active patent estate capable of supporting a conventional first-wave generic challenge.
Any current generic applicant would more likely rely on ordinary ANDA competition after addressing product-specific FDA requirements. The principal risks would involve bioequivalence, manufacturing compliance, supply continuity and commercial pricing rather than patent litigation.
How many patents cover the drug combination?
No material unexpired patent estate is evident for the legacy active ingredients or their basic fixed-dose combination.
Potential historical patent categories include:
- Patents covering perphenazine as a compound.
- Patents covering amitriptyline as a compound.
- Patents covering the combination or its therapeutic use.
- Patents covering tablet composition or manufacturing processes.
Those categories do not create meaningful current protection unless a later patent claims a specific formulation, delivery system or manufacturing process that remains enforceable. The ordinary immediate-release tablets associated with this product have low technical complexity and limited scope for commercially important formulation patents.
What formulations are protected by current patents?
No publicly prominent current formulation franchise is associated with perphenazine and amitriptyline hydrochloride. The marketed product is an immediate-release oral tablet. It is not an extended-release product, depot injection, transdermal system, long-acting formulation or complex multiparticulate dosage form.
A manufacturer could theoretically seek protection for:
- Modified release.
- Taste masking.
- Improved stability.
- A new salt or polymorph.
- A lower-dose combination.
- A manufacturing process.
- A new method of use.
Such patents would need to support a differentiated product with clinical or commercial value. There is no established evidence that these strategies have produced a significant active market for this combination.
Which companies manufacture or market the product?
The current market is generally supplied by generic manufacturers, repackagers and contract manufacturers rather than by the historical Triavil brand owner. FDA labeling and DailyMed listings identify product-specific manufacturers and labelers, but supplier participation can change as companies discontinue low-volume products or transfer abbreviated applications.[1][3]
The market structure typically includes:
| Participant type |
Role |
| ANDA holder |
Owns the FDA-approved generic application |
| Contract manufacturer |
Produces tablets for an ANDA holder or repackager |
| Repackager |
Purchases finished product and distributes under its own label |
| Wholesaler |
Supplies pharmacies and institutional customers |
| Retail or institutional pharmacy |
Dispenses the prescription |
Supplier count is more important than brand recognition. A multi-source market can keep prices low, but products with limited demand may experience intermittent shortages if only one or two manufacturers remain active.
How strong is the patent estate for perphenazine and amitriptyline hydrochloride?
The patent estate is weak from an investment or litigation perspective.
| Patent-strength factor |
Assessment |
| Remaining compound-patent term |
None of commercial significance |
| Remaining composition-of-matter protection |
None of commercial significance |
| Formulation differentiation |
Limited |
| Method-of-use protection |
Historic and unlikely to block generic prescribing |
| Manufacturing patents |
Potentially relevant only to a specific supplier |
| Patent litigation value |
Low |
| Freedom-to-operate risk |
Generally low for standard immediate-release tablets |
The absence of patent strength does not guarantee uninterrupted supply. Generic drug markets can still face manufacturing failures, raw-material constraints, FDA warning letters, plant closures and low-margin exits.
What is the FDA regulatory status of the product?
Perphenazine and amitriptyline hydrochloride remains an FDA-regulated prescription medicine when marketed under an approved application. FDA approval does not indicate that the product is commercially active under a branded name or that every historical manufacturer continues to supply it.
The regulatory profile is mature:
- Prescription-only status.
- Abbreviated generic pathway for equivalent products.
- Immediate-release oral tablet dosage form.
- No biosimilar pathway.
- No current new-drug exclusivity of economic significance.
- Labeling governed by the known safety risks of both active ingredients.
The key regulatory challenge for new entrants is product approval and compliant manufacturing, not clinical development. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence and meet current requirements for chemistry, manufacturing and controls.
Does the drug have biosimilar risk?
No. Biosimilar risk does not apply because perphenazine and amitriptyline hydrochloride is a synthetic small-molecule combination. Competition comes from generic drugs approved through the ANDA pathway, not from biosimilars approved under section 351(k) of the Public Health Service Act.[4]
What is the commercial market size?
Public companies do not generally report standalone revenue for perphenazine and amitriptyline hydrochloride. The product is too old and too small to generate a separately disclosed revenue line in most corporate filings.
The commercial market is likely characterized by:
- Low average selling prices.
- Limited prescription volume relative to modern antidepressants.
- High substitution toward separate generic agents.
- Small absolute revenue per manufacturer.
- Strong pharmacy and payer price sensitivity.
- Minimal promotional spending.
- Low willingness to fund new clinical trials.
Revenue is driven more by retained niche prescribing than by market expansion. The combination may remain useful for patients stabilized on the product, but replacement prescribing tends to favor separate agents that permit independent titration.
What is the financial trajectory for the drug?
The financial trajectory is mature-to-declining, with limited prospects for substantial growth.
Historical phase
The combination benefited from an era when fixed-dose neuropsychiatric products were used more broadly. The original branded product carried commercial value before generic substitution and therapeutic competition intensified.
Generic erosion phase
Once generic products became available, pricing and brand differentiation weakened. Reimbursement shifted toward the lowest-cost equivalent, and branded promotional investment became uneconomic.
Current phase
The product now occupies a niche market. Revenue is likely concentrated among generic suppliers with established manufacturing and distribution infrastructure. Financial performance depends on retaining a small prescription base and avoiding supply interruptions.
Forward trajectory
The base case is gradual volume erosion with periodic price volatility. A supplier could see short-term revenue increases if competitors discontinue production or experience shortages. Those gains would reflect supply concentration rather than durable market expansion.
| Financial driver |
Expected effect |
| Generic substitution |
Negative for price and branded revenue |
| Aging clinical use |
Negative for long-term volume |
| Low manufacturing complexity |
Supports competition |
| Limited supplier participation |
Can support temporary price increases |
| Pharmacy purchasing pressure |
Negative for margins |
| Clinical familiarity |
Supports residual demand |
| New formulation investment |
Unlikely without a clear niche |
There is no evident catalyst comparable to a patent-protected launch, label expansion, orphan indication or premium reformulation.
How does the combination compare with competing drugs?
The combination competes with both separate generic drugs and newer branded therapies.
| Competitive option |
Commercial advantage over the combination |
| Amitriptyline alone |
Allows removal of antipsychotic exposure |
| Perphenazine alone |
Allows treatment of psychosis without tricyclic antidepressant exposure |
| SSRIs |
Generally stronger first-line positioning for depression |
| SNRIs |
Broader use in depression and certain pain conditions |
| Atypical antipsychotics |
More current use in selected augmentation or psychotic-disorder settings |
| Separate antidepressant plus antipsychotic |
Independent dose adjustment |
| Newer fixed-dose products |
Potentially better tolerability or adherence rationale |
The combination retains a practical advantage for patients who respond to both ingredients and prefer one tablet. That advantage is limited by the inability to adjust each drug independently.
What licensing deals affect the product?
No major current licensing transaction is publicly associated with perphenazine and amitriptyline hydrochloride. The historical brand and generic rights are more likely to involve ordinary product transfers, ANDA ownership changes, contract manufacturing and distribution arrangements than strategic licensing.
A licensing deal would have limited economic logic unless it included:
- A differentiated formulation.
- A new therapeutic indication.
- A validated supply advantage.
- A regional distribution opportunity.
- A portfolio strategy involving multiple legacy products.
For the standard immediate-release tablet, the likely value lies in manufacturing scale and reliable supply rather than intellectual property.
What patent litigation or settlement agreements affect the drug?
No major active patent litigation or settlement framework is associated with the legacy combination in the way seen with high-value branded drugs. There is no evident commercial basis for a “first filer versus brand” settlement involving a material remaining patent term.
The more relevant disputes would be ordinary product-quality, supply, labeling or ANDA matters. Those issues can affect availability but generally do not create long-term market exclusivity.
What generic launch scenarios exist?
Base case: stable niche generic supply
Several suppliers continue selling the product at low prices. Prescription volume declines gradually, but established patients maintain a residual market.
Concentrated-supply case
One or two suppliers remain active. A manufacturing interruption produces temporary shortages and price increases. Competitors may re-enter if the price increase persists.
Discontinuation case
Low demand and weak margins cause additional manufacturers to exit. Pharmacies substitute separate perphenazine and amitriptyline products, accelerating the decline of the fixed-dose combination.
Reformulation case
A company develops a modified-release or otherwise differentiated product. This would require new clinical and regulatory investment and is not supported by an evident current commercial catalyst.
What geographic markets are relevant?
The United States is a mature generic market with limited branded opportunity. The combination may have residual demand in other countries where older psychiatric medicines remain in use, but regulatory status, brand ownership, prescribing practices and reimbursement differ by jurisdiction.
Geographic expansion would face:
- Country-specific registration requirements.
- Local pharmacovigilance obligations.
- Differing treatment guidelines.
- Regional manufacturing rules.
- Price controls.
- Limited physician demand for fixed-dose therapy.
The product’s age makes global launch economics difficult unless the manufacturer already has a broad generic distribution platform.
Key Takeaways
- Perphenazine and amitriptyline hydrochloride is a legacy fixed-dose psychiatric tablet associated historically with Triavil.
- The product has no meaningful remaining new-drug or patent exclusivity.
- It competes as a low-price generic against separate agents and newer psychiatric therapies.
- Paragraph IV litigation, biosimilar competition and patent-settlement risk are commercially immaterial.
- Public companies do not generally disclose standalone sales, indicating limited revenue materiality.
- The market’s likely trajectory is gradual volume decline, with temporary pricing opportunities if supply becomes concentrated.
- The main barriers are FDA approval, compliant manufacturing and reliable distribution, not intellectual property.
- A material financial upside would require a differentiated formulation, supply shortage or new therapeutic positioning.
FAQs
Is perphenazine and amitriptyline hydrochloride still available in the United States?
Generic tablets have historically been marketed in several strengths, but availability can vary by manufacturer, wholesaler inventory and pharmacy supply. The product should be evaluated through current FDA and DailyMed listings rather than historical brand status.
What was the brand name for perphenazine and amitriptyline hydrochloride?
The best-known historical brand was Triavil. The commercial significance of that brand has largely disappeared following generic substitution.
Can perphenazine and amitriptyline hydrochloride be replaced with separate tablets?
Clinicians may prescribe the two active ingredients separately when clinically appropriate. Separate dosing allows independent adjustment but changes the patient’s regimen and requires prescriber evaluation.
Is perphenazine and amitriptyline hydrochloride a controlled substance?
The combination is not generally classified as a controlled substance under the federal Controlled Substances Act. Its components remain prescription medicines with significant safety and monitoring considerations.
Does the product have an opportunity for a 505(b)(2) reformulation?
A reformulation could theoretically use a 505(b)(2) pathway if it relied partly on existing safety or efficacy information. Commercial viability would depend on proving a clinically meaningful advantage over inexpensive generic tablets.
References
- DailyMed. (n.d.). Perphenazine and amitriptyline hydrochloride tablet: Prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
- U.S. National Library of Medicine. (n.d.). DailyMed: Current prescribing information for FDA-approved drugs. https://dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable biosimilar products. https://www.fda.gov
